Morgan Stanley Updates Gilead Sciences' Outlook Ahead of Q1 Earnings
Morgan Stanley raised its price target for Gilead Sciences (GILD) to $175 from $171, maintaining an Overweight rating. The update is based on revised financial models and industry data trends. Gilead also announced expanded global access to its HIV prevention therapy lenacapavir, targeting 3 million people in high-incidence regions by 2028.
Topics: HIV prevention pharmaceutical partnerships price target stock outlook